Alcoholic Hepatitis - Pipeline Review, H1 2020

March 2020 | 101 pages | ID: A8C1067D5A3EN
Global Markets Direct

Abstracts

Alcoholic Hepatitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H1 2020, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcoholic Hepatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcoholic Hepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Alcoholic Hepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Alcoholic Hepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Alcoholic Hepatitis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Alcoholic Hepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Alcoholic Hepatitis - Overview
Alcoholic Hepatitis - Therapeutics Development
Alcoholic Hepatitis - Therapeutics Assessment
Alcoholic Hepatitis - Companies Involved in Therapeutics Development
Alcoholic Hepatitis - Drug Profiles
Alcoholic Hepatitis - Dormant Projects
Alcoholic Hepatitis - Discontinued Products
Alcoholic Hepatitis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Alcoholic Hepatitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Alcoholic Hepatitis - Pipeline by Afimmune Biopharma Ltd, H1 2020
Alcoholic Hepatitis - Pipeline by Cadila Healthcare Ltd, H1 2020
Alcoholic Hepatitis - Pipeline by DURECT Corp, H1 2020
Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corp Ltd, H1 2020
Alcoholic Hepatitis - Pipeline by Gilead Sciences Inc, H1 2020
Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals Inc, H1 2020
Alcoholic Hepatitis - Pipeline by Novartis AG, H1 2020
Alcoholic Hepatitis - Pipeline by Pattern Therapeutics, H1 2020
Alcoholic Hepatitis - Pipeline by PharmaKing Co Ltd, H1 2020
Alcoholic Hepatitis - Dormant Projects, H1 2020
Alcoholic Hepatitis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Alcoholic Hepatitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Afimmune Biopharma Ltd
Cadila Healthcare Ltd
DURECT Corp
Generon (Shanghai) Corp Ltd
Gilead Sciences Inc
Intercept Pharmaceuticals Inc
Novartis AG
Pattern Therapeutics
PharmaKing Co Ltd
Rejuvenation Technologies Inc
Vectus Biosystems Ltd
Verlyx Pharma Inc
Virpharm Pharmaceutical Co